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ABSTRACT: Mucin-type O-glycosylation is initiated by a family
of polypeptide GalNAc-transferases (GalNAc-Ts) which are type-
II transmembrane proteins that contain Golgi luminal catalytic
and lectin domains that are connected by a ﬂexible linker. Several
GalNAc-Ts, including GalNAc-T4, show both long-range and
short-range prior glycosylation speciﬁcity, governed by their lectin
and catalytic domains, respectively. While the mechanism of the
lectin-domain-dependent glycosylation is well-known, the molec-
ular basis for the catalytic-domain-dependent glycosylation of
glycopeptides is unclear. Herein, we report the crystal structure of
GalNAc-T4 bound to the diglycopeptide GAT*GAGA-
GAGT*TPGPG (containing two α-GalNAc glycosylated Thr
(T*), the PXP motif and a “naked” Thr acceptor site) that
describes its catalytic domain glycopeptide GalNAc binding site.
Kinetic studies of wild-type and GalNAc binding site mutant
enzymes show the lectin domain GalNAc binding activity dominates over the catalytic domain GalNAc binding activity and that
these activities can be independently eliminated. Surprisingly, a ﬂexible loop protruding from the lectin domain was found
essential for the optimal activity of the catalytic domain. This work provides the ﬁrst structural basis for the short-range
glycosylation preferences of a GalNAc-T.
Mucin-type O-glycosylation (O-GalNAc-type) is one ofthe most diverse and complex types of protein O-
glycosylation found in higher eukaryotes and is likely the most
abundant, with over 80% of all proteins passing through the
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secretory pathway predicted to be O-glycosylated.1 This post-
translational modiﬁcation is important in a wide range of
cellular/biological processes,1 including phosphate homeo-
stasis and bone mineralization,2 regulation of HDL and
LDL,3,4 tumorigenesis and formation of metastasis,5,6 organo-
genesis and development,7 and the fundamental process of
ectodomain shedding and cell signaling.8,9 In addition,
alteration of the cellular location and regulation of the activity
of the GalNAc-T isoenzymes have clear implications in
disease.1 Mucin-type O-glycosylation (henceforth called O-
glycosylation) is initiated by a large family of GalNAc-T
isoenzymes (20 members in humans and similar numbers in
most mammals) that are suggested to act in a hierarchical
manner. GalNAc-Ts are retaining glycosyltransferases (GTs)
that transfer a GalNAc moiety from uridine diphosphate N-
acetylgalactosamine (UDP-GalNAc) onto Ser/Thr residues of
proteins.1 The GalNAc-Ts are unique among metazoan GTs
because in addition to their N-terminal catalytic domain
adopting a GT-A fold, they possess a C-terminal GalNAc
binding lectin domain with a β-trefoil fold, which provides
additional functions to these enzymes.10−12 The two domains
are linked through a short ﬂexible linker whose motion has
been suggested to be responsible for the dynamic conforma-
tional landscape of these enzymes.13 Three distinctive modes
of substrate glycosylation have been reported:10 (1) glyco-
sylation of “naked” unglycosylated peptides; (2) glycosylation
of GalNAc-containing glycopeptides where the sites of
glycosylation are 1−3 residues away from the prior glycosite,
hereafter termed short-range or neighboring glycosylation; and
(3) glycosylation of GalNAc glycopeptides where the sites of
glycosylation are ∼5−17 residues away from the prior
glycosite, termed long-range or remote glycosylation.10 The
latter, long-range glycosylation activity is due to glycopeptide
GalNAc binding at the lectin domain, directing the acceptor
peptide onto the catalytic domain in an N- and/or C-terminal
direction.10,14 Most isoforms that contain a lectin domain have
been found to possess this remote glycosylation activity.10 On
the other hand, sites adjacent and neighboring to an existing
GalNAc glycosite are glycosylated in a catalytic-domain-
dependent manner, with GalNAc-T4 being part of a small
number of GalNAc-Ts (including GalNAc-T7, -T10, and
-T12) that have been shown to glycosylate contiguous or
nearby sites.10,11,15 While GalNAc-T4 glycosylates acceptor
sites that are directly C-terminal to a prior GalNAc glycosite,
GalNAc-T7 and T10 glycosylate sites that are directly N-
terminal from a prior site of GalNAc glycosylation. In addition,
GalNAc-T12 glycosylates sites located three residues N-
terminal from a prior GalNAc glycosite.10 Thus, it is likely
that a GalNAc binding site should exist for those isoenzymes
that possess short-range glycosylation preferences on glyco-
peptides. While the lectin domain GalNAc binding sites have
been well-characterized by others and us for several GalNAc-
Ts,16,17 the catalytic domain GalNAc binding site has never
been revealed at the structural level. In addition, it is not
known how GalNAc-T4, -T7, and -T10 may glycosylate
contiguous acceptor sites in glycopeptides exclusively using a
catalytic-domain-dependent manner.
Previous structural work from our lab with GalNAc-T2 in
complex with “naked” peptides has provided insight into the
catalytic-domain-mediated transfer of GalNAc from the UDP-
GalNAc donor to the peptide acceptor. In addition, our studies
on remotely glycosylated glycopeptides have demonstrated
how the GalNAc-T2 lectin domain guides N-terminal acceptor
sites into the catalytic domain for catalysis to take place, by
binding to a distant prior GalNAc glycosite located at the C-
terminus of the substrate.12,13,18 Recently, we have also
demonstrated how other GalNAc-T isoforms such as
GalNAc-T3, -T4, -T6, and -T12 achieve the opposite long-
range glycosylation preferences.10,19 In that study we showed
that the connecting interdomain ﬂexible linker dictates the
orientation of the lectin domain with respect to the catalytic
domain. Thus, the diﬀerent positions of the lectin domain
GalNAc binding site of GalNAc-T4 relative to GalNAcT2
readily explained how these two isoenzymes achieved their
opposite and distinct long-range glycosylation preferences.14
To date however no structural studies have revealed how the
catalytic domains of any of the GalNAc-Ts that possess
neighboring or adjacent glycopeptide activities actually
accommodate an acceptor peptide with a GalNAc residue
immediately adjacent to the acceptor site. Such knowledge
would help us to understand how these transferases perform
their so-called ﬁlling-in activities, i.e., completing the
glycosylation of heavily O-glycosylated mucin domains. The
GalNAc-T4 isoform is of particular interest as it is the only
isoform shown capable of glycosylating two out of the ﬁve
acceptor sites in the partially glycosylated MUC1 mucin
tandem repeat.11 The density of glycosylation, together with
the structure of O-glycans in the mucin tandem repeat regions,
are important features for the exploitation of the cancer related
glycoforms of MUC1 as diagnostic as well as therapeutic
purposes.20 Generally, GalNAc-T4 glycosylates very few
isolated sites in “naked” peptide acceptors.21
We report herein a multidisciplinary approach combining
diﬀerent structural and biophysical techniques, with enzyme
Table 1. Peptide Acceptor Substrates Used in This Studya
aNote: T* denotes the Thr-O-GalNAc moiety.
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kinetics analysis and computational studies on GalNAc-T4.
Our ﬁndings combined with the kinetic characterization of a
library of (glyco)peptides, against the wild-type and inactivat-
ing catalytic and lectin domain mutant transferases, have begun
to reveal the molecular basis of the short-range glycosylation
preferences of the GalNAc-T4 on glycopeptide substrates. The
experiments further reveal the dominant role of long-range
lectin domain glycopeptide binding over short-range catalytic
domain glycopeptide binding in the overall glycosylation
process of GalNAc-T4. In addition, we determine the role of a
ﬂexible loop protruding from the lectin domain as an
important structural feature essential for the optimal activity
of the catalytic domain.
■ RESULTS AND DISCUSSION
Kinetics of GalNAc-T4 against Glycopeptide Sub-
strates. We have previously used three model (glyco)peptides
(Table 1) to compare the long-range glycosylation preferences
and enzyme kinetics of GalNAc-T2 and -T4.14 Those were the
“naked” peptide 1 (denoted -TT-, for simplicity), and the C-
and N-terminal glycosylated monoglycopeptides, 2 and 3
(denoted -TT--T*- and -T*--TT-, respectively, where T*
represents a GalNAc-glycosylated Thr, see Table 1 and Figure
1a).14 Here, we have expanded this (glyco)peptide library with
monoglycopeptide 4 (denoted -T*T-) and diglycopeptides 5
and 6 (denoted -T*T--T*- and -T*--T*T-, respectively)
(Table 1). The diglycopeptides were designed to evaluate the
combined eﬀects of having long-range and short-range prior
glycosylation in the same substrate. Note that all substrates in
Table 1 have one or two potential Thr acceptor sites (i.e.,
-T*T- or -TT-) that also contain an adjacent C-terminal PXP
motif (as -PGP-), which is recognized by most GalNAc-Ts.10,13
These peptides also share the same amino acid sequence
around the acceptor site, thus eliminating the eﬀects of peptide
sequence variation on catalysis (Table 1). The short sequences
surrounding the remote prior T* glycosylation site are also
identical, thus ensuring nearly identical lectin domain binding
properties. Note that the remote prior T* glycosylation site is
located 7−8 residues away from the potential Thr acceptor
sites, which is in agreement with the optimal distance of 7−11
residues observed for the long-range glycosylation of GalNAc-
T4.10 Likewise the neighboring N-terminal prior glycosylation
preference of GalNAc-T4,10 i.e., -T*T-, was included in
glycopeptides 5 and 6 in order to examine the combined
eﬀects of having both long- and short-range prior glycosylation
in one glycopeptide. For simplicity we did not include in our
present studies peptides bearing Ser acceptor sites or S*, since
Ser is usually less eﬃciently glycosylated than Thr,18 and S*
displays distinct conformational preferences in contrast to T*,
both in the free state and bound to proteins.22 According to
our previous crystal structure of GalNAc-T4 complexed with
peptide 3 (-T*--TT-),14 the remote N-terminal glycosites (i.e.,
T*) of both peptides 3 and 6 (-T*--TT- and -T*--T*T-)
would bind to the GalNAc binding site of the lectin domain,
while directing the C-terminal of the peptide acceptor onto the
catalytic domain for catalysis. In contrast, the remote C-
terminal glycosite of peptides 2 (-TTT*-) and 5 (-T*T
T*-), when bound to the lectin domain, would not be expected
to correctly orient the N-terminal portion of the acceptor
peptide onto the catalytic domain for eﬃcient GalNAc transfer.
Figure 1. Biophysical characterization of GalNAc-T4. (a) Peptide glycosylation kinetics of GalNAc-T4 against (glyco)peptides 1−6 (see also
Figure 4a). Michaelis−Menten kinetic values, Km, Vmax, and catalytic eﬃciency (Vmax/Km) for glycopeptides 3−6 were obtained from the nonlinear
least-squares ﬁt to the initial rate data, obtained as described in the Methods section and given in Table 2. Peptide substrates 1 and 2 are largely
unglycosylated by GalNAc-T4.14 (b) Left panel: SPR sensogram for binding of glycopeptide 6 to GalNAc-T4. Right panel: Fitting of the SPR
binding data giving a Kd of 70 ± 15 μM. (c) Mapping of substrate binding epitopes by saturation transfer diﬀerence (STD) NMR. The size of the
colored spheres represents the normalized STD-NMR intensity (i.e., binding) observed for the indicated protons/residues. For sake of clarity, the
STD response given for the indicated amino acid residues corresponds to the average of STD for all of the protons in the residue that could be
accuracy measured. See Figures S4−S6 for the detailed STD-NMR enhancements of the identiﬁed residues/protons. Note that in addition to the
GalNAc protons amino acid protons in the -T*TPGP- sequence also gave STD-NMR enhancements. (d) Representative 600 MHz 1H NMR
spectra of glycopeptide 6 (-T*--T*T-) at 877 μM in the presence of 13.5 μM GalNAc-T4, 75 μM UDP, and 75 μMMnCl2 obtained at 298 K. The
oﬀ resonance reference spectrum (labeled Oﬀ res) is displayed in blue, and the on resonance STD spectrum (labeled STD) is in red. Key proton
resonances are labeled in the STD spectrum. Note the diﬀerent STD responses for the identiﬁed GalNAc H2 protons of the glycosylated Thr3 and
Thr11 found between 4.0 and 4.1 ppm of the STD spectrum.
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To test the rationale above, detailed enzyme kinetics of
GalNAc-T4 against the (glyco)peptides listed in Table 1 was
performed using UDP-3H-GalNAc as donor (see the Methods
section for details). Plots of initial rates versus substrate
concentration are given in Figure 1a, while the obtained kinetic
constants are listed in Table 2. Note that the results for
peptides 3, 4, and 5 could be ﬁtted to a standard Michaelis−
Menten model, while peptide 6 was best ﬁtted to a model
which included apparent substrate inhibition and will be
discussed below. As can be readily seen from Figure 1a,
glycopeptides 3 (-T*--TT-) and 6 (-T*--T*T-) show the
largest activity, which is ∼10-fold higher than that for
glycopeptides 4 (-T*T) and 5 (-T*T--T*-). As previously
reported, peptides 1 (-TT-) and 2 (-TT--T*-) were
imperceptibly glycosylated.14 Note also that only the second
Thr is glycosylated in those peptides containing the -TTPGP-
sequence.14 These results are consistent with our previous
ﬁndings that GalNAc-T4 displays a directly neighboring N-
terminal prior glycosylation preference, as well as a long-range
N-terminal prior glycosylation activity, while showing poor
activity against the naked peptide or glycopeptides containing
only a C-terminal remote prior glycosylation.10 Thus, for
glycosylation to take place in glycopeptide 4 (-T*T), it can be
concluded that the neighboring glycosylated Thr must directly
bind to the catalytic domain as the acceptor Thr is contiguous
to this site. The similar plots and kinetic constants obtained for
diglycopeptide 5 (-T*T--T*-) and monoglycopeptide 4
(-T*T-), (Figure 1a and Table 2) suggest that the
glycosylation of diglycopeptide 5 may be dominated by
-T*T- binding at the catalytic domain rather than binding of
the remote C-terminal T* at the lectin domain. This agrees
with the imperceptibly low activity of glycopeptide 2 (-TT--
T*-), which we take as evidence that the C-terminal glycosite
either did not to bind the lectin domain, or if bound, it failed to
correctly orient the N-terminal acceptor region of the substrate
into the catalytic domain.14 However, as discussed below, our
kinetic studies of the GalNAc-T4 lectin mutant suggest that
the lectin domain may play some role in the observed activity
of diglycopeptide 5.
The comparison of the two most active monoglycopeptides
3 (-T*--TT-) and 4 (-T*T-) reveals the dominant inﬂuence of
the remote N-terminal prior glycosylation on enzyme activity,
Table 2. Kinetic Parameters for the Wild-Type and Mutant GalNAc-T4
aKinetic values and R2 obtained from the GraphPad Michaelis−Menten ﬁt of the plots in Figures 1a and 4. bKinetic values and R2 obtained from
the GraphPad Michaelis−Menten ﬁtting with substrate inhibition of the plots in Figure 4. cCat Eﬀ, catalytic eﬃciency obtained from the Vmax/Km
ratio. dUDP-GalNAc hydrolysis obtained from Sephadex G10 chromatography summarized in Figure S8.
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where peptide 3 has a ∼8-fold higher Vmax, ∼12-fold lower Km,
and a ∼100-fold higher catalytic eﬃciency (Vmax/Km)
compared to peptide 4 (Table 2). This inﬂuence of the lectin
domain is also observed for diglycopeptide 6 (-T*--T*T-),
which possesses both remote and neighboring glycosites N-
terminal of the acceptor site (Figure 1a). However, the kinetic
plot for diglycopeptide 6 was best ﬁtted to a Michaelis−
Menten model with substrate inhibition (Figure 1a, Table 2).
The Km of peptide 6 (-T*--T*T-) is ∼1.3-fold lower than that
for peptide 3 (-T*--TT-) (∼39 vs ∼51 μM) suggesting a weak
synergistic eﬀect of the two glycosites in peptide 6, each
binding separately to the lectin and catalytic domains of the
enzyme. This fact implies that substrate binding to the enzyme
is slightly stronger when both the lectin and catalytic domains
bind GalNAc residues with the appropriate N-terminal
placement, as found for the diglycosylated substrate. This
synergistic eﬀect is clearly observed in the substrate Kd values
obtained by surface plasmon resonance (SPR) in the presence
of excess of UDP and MnCl2 (see the Methods section). While
the Kd values for both monoglycopeptides 4 (-T*T-) and 3
(-T*--TT-) were relatively weak (in the mM range; see Figure
S1 and ref 14), the Kd value for diglycopeptide 6 (-T*--T*T-)
was 70 ± 15 μM (Figure 1b). Interestingly, the observed Km
values for these three glycopeptides are lower than their Kd
values, especially for glycopeptides 3 and 6. The discrepancies
between GalNAc-T4’s higher-aﬃnity Km values obtained from
our kinetics studies (Table 2) and the Kd values obtained from
direct binding studies, particularly for peptide 3, can be
attributed to the fact that the UDP-GalNAc donor was present
in the enzyme kinetics, but absent in the SPR binding
studies.14 UDP-GalNAc stabilizes the so-called ﬂexible loop of
the catalytic domain active site in a “closed” conformation,
which completes the formation of the peptide-binding groove
and leads to an active transferase.13,14,18 Thus, our SPR studies
in the absence of UDP-GalNAc likely represent the weak
binding of peptide substrate to the “open” ﬂexible loop
conformation of the enzyme. However, this discrepancy is not
as large for peptide 6, where Kd is only ∼2-fold higher than the
Km observed from the kinetic analysis. This suggests that the
high binding aﬃnity of peptide 6 (due to GalNAc binding at
both domains) might further stabilize/drive the GalNAc-T4’s
catalytic domain ﬂexible loop in a closed conformation in the
presence of either UDP-GalNAc or UDP (as conﬁrmed by the
crystal structure discussed below). The synergistic eﬀects
observed in the kinetic and Kd values obtained for
diglycopeptide 6 (-T*--T*T-) compared to monoglycopep-
tides 3 (-T*--TT-) and 4 (-T*T) are due to the divalency of
peptide 6, which may simultaneously or consecutively bind to
both the lectin and catalytic domains of the transferase. Such
synergy is common to multivalent carbohydrate−lectin binding
systems.23,24 In summary, the initial catalytic eﬃciency (Vmax/
Km) of peptide 6 (-T*--T*T-) is ∼1.5- and ∼150-fold higher
than the catalytic eﬃciency of peptides 3 (-T*--TT-) and 4
(-T*T-), respectively, showing again that the remote T*
binding to the lectin domain dominates overall catalytic
eﬃciency. It is also worth noting that the much higher catalytic
eﬃciencies of glycopeptides 3 and 6 compared to those
deduced for glycopeptides 4 and 5 correlate with their extent
of nonproductive hydrolysis of UDP-GalNAc by the trans-
ferase, where glycopeptides 3 and 6 display only ∼5%
hydrolysis, while glycopeptides 4 and 5 display ∼20%
hydrolysis (Table 2 and the Methods section). Likewise,
peptides 1 and 2, with extremely low catalytic eﬃciencies,
display even higher rates of hydrolysis of ∼40−50% (Figure
S8).14
As mentioned above, the kinetic plot for diglycopeptide 6
(-T*--T*T-) is best ﬁtted to a Michaelis−Menten kinetic
model that includes substrate inhibition (Figure 1a and Table
2). The appearance of substrate inhibition at high diglycopep-
tide 6 concentration could be due to the nonproductive
binding of the neighboring GalNAc in the -T*TPGP-
sequence at the lectin domain. Such a binding event would
compete with the “productive” binding of the remote GalNAc
(-T*-) at the lectin domain and would lead to the observed
decrease in activity at high substrate concentration. This
explanation implies that the binding aﬃnity of the -T*TPGP-
epitope at the lectin domain is weaker than that of the remote
T* GalNAc of glycopeptide 6. In this case, the glycosylation
rate at high substrate concentration, would ideally be ∼1/2 of
the initial maximum rate, as indeed observed (Figure 1a).
GalNAc-T4−Substrate Interactions with (Glyco)-
peptide Substrates by STD-NMR. To further characterize
the diﬀerent modes of glycopeptide substrate binding to
GalNAc-T4, we performed saturation transfer diﬀerence
(STD) NMR experiments on the substrates in Table 1, in
the presence of GalNAc-T4, UDP, and MnCl2, as described in
the Methods section. Our previous STD-NMR studies with
peptides 1−3 (-TT-, -TT--T*-, -T*--TT-)14 have revealed
diﬀerent features: (1) No signiﬁcant STD enhancements were
observed for peptide 1 (-TT-), suggesting that it poorly binds
GalNAc-T4, in agreement with its very low glycosylation rate.
(2) Poor recognition of the peptide residues was revealed in
glycopeptides 2 and 3 (-TT--T*-, -T*--TT-). (3) Signiﬁcant,
but diﬀerent, STD intensity patterns for the GalNAc protons
of glycopeptides 2 and 3, suggesting the existence of diﬀerent
binding modes, were probably related to their diﬀerent rates of
glycosylation14 (Figure S2). These STD-NMR results were
further supported by the crystal structure of the complex of
GalNAc-T4-UDP-Mn2+-glycopeptide 3, which shows the
GalNAc moiety of glycopeptide 3 bound to the GalNAc
binding site at the lectin domain.14
Here, we continued these STD-NMR studies with the new
glycopeptides 4, 5, and 6 (-T*T-, -T*T−T*-, and −T*--T*T-
). In contrast to monoglycopeptides 2 and 3, glycopeptides 4,
5, and 6 show signiﬁcant STD-NMR enhancements for the
protons of the Thr and Pro residues comprising the -T*TPGP-
peptide sequence (Figure 1c, Figures S2−S6 and Tables S1−
S3). The GalNAc moieties in 4, 5, and 6 also gave clear STD-
NMR enhancements for the methyl protons of the GalNAc N-
acetyl group (NHAc) (>75%, Figures S2−S6 and Tables S1−
S3). However, diﬀerences in the relative STD-NMR enhance-
ments of the GalNAc ring protons are clearly observed
between glycopeptides 3, 4, 5, and 6. When comparing
monoglycopeptides 3 and 4, (-T*--TT- and -T*T-) the
highest STD-NMR responses are observed for the H2, H4, and
NHAc methyl protons in 3, while H3 and NHAc methyl
protons give the largest STD-NMR enhancements in 4 (Figure
1c and Figure S4). These diﬀerences in the STD-NMR
intensities between glycopeptides 3 and 4 suggest diﬀerent
recognition modes of the GalNAc moieties by the transferase,
fully consistent with their proposed binding at the lectin and
catalytic domains, respectively. The observed STD-NMR
enhancements for the protons of the Thr, Pro, and GalNAc
moieties in the -T*TPGP- acceptor sequence of monoglyco-
peptide 4 are consistent with the GalNAc residues interacting
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at the catalytic domain rather than at the lectin domain (see
below).
For diglycopeptides 5 and 6 (-T*T--T*- and -T*--T*T-),
given the observed extensive overlapping, most of the observed
STD-NMR enhancements in the GalNAc residue represent the
combined STD from both GalNAc residues. Nevertheless, the
individual NHAc methyl resonances from the diﬀerent
GalNAc residues in 5 and 6 were well-resolved, showing
high STD-NMR enhancements (Figures S5 and S6), which
suggests that both NHAc groups are bound. In contrast, the
STD-NMR response for the resolved H2 protons of the two
GalNAc residues in 6 are rather diﬀerent (Figure 1c and
Figures S5 and S6). The H2 proton of the GalNAc at Thr3
(i.e., the remote lectin bound GalNAc) shows a much stronger
STD (90%) than that (50%) at Thr11 (i.e., the catalytic
domain bound neighboring GalNAc-). This low STD response
for the H2 proton of the GalNAc at Thr11 in 6 (-T*--T*T-) is
similar to that observed for the monoglycopeptide 4 (-T*T-)
and strongly suggests that the neighboring GalNAc moiety in 6
also preferentially binds to the catalytic domain of GalNAc-T4.
This is again supported by the observation of STDs for the
Figure 2. Crystal structure of GalNAc-T4 in complex with UDP-Mn+2 and glycopeptide 6. (a) Two diﬀerent views of GalNAc-T4 in complex with
6. The catalytic and lectin domains are colored in gray, and the ﬂexible linker and catalytic domain active site loop are depicted in red and yellow,
respectively. The lectin domain ﬂexible loop (LFL) is indicated by a black arrow. The GalNAc moiety of the Thr3-GalNAc and Thr11-GalNAc is
shown as orange carbon atoms while the rest of the peptide is shown as green carbon atoms. The nucleotide is depicted as brown carbon atoms
whereas the manganese atom is shown as a pink sphere. Inserted between the structures is a surface representation of GalNAc-T4 with the same
orientation as the cartoon representation of the leftmost structure. (b) Electron density maps are FO−FC (blue) contoured at 2.0 σ for glycopeptide
6, UDP, and manganese ion. (c) Two diﬀerent views of GalNAc-T2 in complex with MUC5AC-13 (PDB entry 5AJP14) again with an inserted
surface representation between structures. Atom colors are the same as in part a above. (d) Close-up views of the GalNAc-T2-UDP-MUC5AC-13
and the GalNAc-T4-UDP-glycopeptide 6 complexes showing the bound glycopeptide and the catalytic domain active site ﬂexible loop (in black).
Note that ﬂexible loop residues Trp331 in GalNAc-T2 and Trp334 in GalNAc-T4 adopt an “in” loop conformation.
ACS Central Science Research Article
DOI: 10.1021/acscentsci.8b00488
ACS Cent. Sci. 2018, 4, 1274−1290
1279
protons of the peptide residues of the -T*TPGP- acceptor
sequence in both 4 and 6 (Figure 1c and Figures S4 and S6).
On the other hand, there are no STD enhancements for the
peptide backbone of glycopeptides 2 and 3, which lack the
neighboring GalNAc-Thr residue in the acceptor sequence,
-TTPGP-,14 while STD enhancements are clearly present in
glycopeptides 4, 5, and 6, whose acceptor sequences do
contain it. This, taken together with the diﬀerent STD-NMR
patterns for the GalNAc protons and the higher activities of
the -T*T- containing peptides compared to the -TT-
analogues (particularly 1 vs 4 and 2 vs 5), strongly suggests
that the neighboring GalNAc in -T*T- and the ﬂanking -PGP-
motif together increase peptide substrate binding (in the
absence of a remote N-terminal prior glycosite). Furthermore,
this binding event must speciﬁcally occur at the catalytic
domain, since the GalNAc moiety is transferred to the free Thr
in the -T*TPGP- acceptor sequence upon catalysis.
Glycopeptides 3 and 6 (-T*--TT- and -T*--T*T-), which
show the highest Vmax and catalytic eﬃciency of all of the
peptides (Table 2), nevertheless display dramatically diﬀerent
STD-NMR enhancements at their -TTPGP- and -T*TPGP-
acceptor sequences. In fact, 6 provides high STDs, while 3
does not give any enhancements. This is consistent with a
binding event between the remote N-terminal prior glycosite
and the lectin domain in both glycopeptides, while only in 6 is
there tight binding at the catalytic domain due to the presence
of a neighboring glycosite in the acceptor T*TPGP sequence.
This is in keeping with our earlier structure of 3 (-T*--TT-)
bound to GalNAc-T4, which revealed no electron density for
the peptide bound to the catalytic domain and the lack of STD
enhancements for the acceptor -TTPGP- sequence. Therefore,
the combination of kinetics and STD-NMR results provides
strong evidence that a separate peptide GalNAc binding exists
in the catalytic domain of GalNAc-T4 that accounts for its N-
terminal short-range neighboring glycosylation preference.
Crystal Structure of GalNAc-T4 in Complex with UDP-
Mn2+ and Glycopeptide 6 (-T*--T*T-). To identify the
catalytic domain (neighboring) GalNAc-peptide binding site
on GalNAc-T4 and to further understand how the transferase
recognizes both donor and glycopeptide acceptors, we
obtained triclinic crystals of GalNAc-T4 that were sub-
sequently soaked with diglycopeptide 6, UDP, and MnCl2.
The resulting crystal was solved giving a structure of the
transferase/diglycopeptide complex at 1.80 Å resolution,
containing two independent GalNAc-T4 molecules in the
asymmetric unit (Table S4). The obtained structure shows a
compact GT-A fold and a lectin domain located at the N- and
C-terminal regions of the transferase, respectively. Moreover, a
clear structure of diglycopeptide 6 is evident bound to both
domains (Figure 2a). Additionally, the structure clearly shows
the ﬂexible linker connecting both domains and the ﬂexible
loop of the catalytic domain (Figure 2a), which account for the
distinct long-range glycosylation preferences and for the
inactivation/activation process of these enzymes, respec-
tively.14,18 In our earlier crystal structure of GalNAc-T4
complexed with 3 (-T*--TT-), the ﬂexible loop at the catalytic
Figure 3. Structural features of peptide, UDP, and lectin-domain-binding sites of GalNAc-T4. (a) View of the complete sugar nucleotide, peptide,
and lectin-domain-binding sites of the GalNAc-T4-UDP-glycopeptide 6 complex. Upper panel: close-up view of bound glycopeptide. Lower panel:
close-up view of the manganese binding site. The residues forming sugar-nucleotide, peptide, and lectin-domain-binding sites are depicted as black,
yellow, and gray carbon atoms, respectively. UDP and the glycopeptide are shown as brown and green carbon atoms, respectively. Mn2+ and
GalNAc moiety are depicted as a pink sphere and orange carbon atoms, respectively. Hydrogen bond interactions are shown as dotted green lines.
Water molecules are depicted as red spheres. Note that we only show water-mediated interactions in which only one water molecule acts as a bridge
between the residues. (b) View of the sugar nucleotide, glycopeptide, and lectin-domain-binding sites of the GalNAc-T2-UDP-MUC5AC-13
complex (PDB entry 4D0T). Colors are the same as above. (c) Modeled structure for a GalNAc-T4-UDP-GalNAc-glycopeptide 6 complex. The
coordinates of the UDP-GalNAc were obtained by superposing the structure of GalNAc-T2 containing UDP-GalNAc (PDB entry 4D0T) with the
GalNAc-T4-UDP-GalNAc-glycopeptide 6 complex. The structure shows that the Thr12 acceptor of glycopeptide 6 is close to the anomeric carbon
of UDP-GalNAc.
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domain was disordered, and no density for glycopeptide 3
could be observed at the catalytic domain.14 In contrast, the
present structure of GalNAc-T4-UDP/Mn2+ complexed with 6
(-T*--T*T-) shows both structural features fully ordered
(Figure 2a). This is likely due to the stabilization provided by
the binding of both UDP and the GalNAc-containing peptide
to the catalytic domain (Figure 2a,b). Herein, a loop
protruding from the lectin domain toward the catalytic domain
glycopeptide binding site is also evident, which we have called
the “lectin ﬂexible loop” (Figure 2a residues 460−472;
hereafter named LFL). This LFL motif has not been previously
described for other GalNAc-T structures, and its signiﬁcance
will be discussed below.
Comparison between the GalNAc-T4 and T2 Struc-
tures Bound to Glycopeptides. The GalNAc-T4 structure
complexed with 6 (-T*--T*T-) and UDP/Mn2+ was compared
(Figure 2c) to that of GalNAc-T2 bound to withMUC5AC-13
(GTTPSPVPTTSTT*SAP) and UDP/Mn2+ (PDB entry
5AJP). The observed diﬀerent orientations of the lectin
domain account for the distinct long-range/remote prior
glycosylation preferences of these transferases, i.e., for N-/C-
terminal glycosites, respectively (compare left panels and space
ﬁlled inserts of Figure 2a,c).14 In addition, in both crystal
structures, the ﬂexible loop of the catalytic domain (residues
363−374 in GalNAc-T4 and residues 360−372 in GalNAc-T2;
see Figure S7) adopts the so-called “closed conformation”,
indicating an active state structure. The active form of the
GalNAc-T4-6 complex is further supported by the presence of
the so-called “in conformation” of the catalytic Trp334
(Trp331 in GalNAc-T2, Figure 2d).13 On this basis, the
crystal structure of GalNAc-T4 bound to UDP and 6 describes
the active conformation.
Lectin Domain Substrate Binding. The remote GalNAc
moiety (Thr3-GalNAc of 6) bound at the lectin domain is
tethered by hydrogen bonds by the conserved residues
Asp459/His478/Asn483 (Figure 3a) (for GalNAc-T2,
Thr13-GalNAc of MUC5AC-13 interacts with Asp458/
His474/Asn479, Figure 3b). In addition, CH−π interactions
are also observed between the Thr3-GalNAc moiety and
Phe475 of GalNAc-T4 (Tyr471 in GalNAc-T2) (Figure 3a,b).
Out of the 16 residues of 6, ∼1/4 (i.e., Gly4-Ala7) are fully
exposed to the solvent when bound to GalNAc-T4, while this
is not observed for the homologous MUC5AC-13 bound to
GalNAc-T2 (Figure 3a,b). This implies there may be a gap in
substrate binding between the lectin domain GalNAc binding
site and the catalytic domain (glyco)peptide binding site that
has not been observed for GalNAc-T2 (see the surface
representations in Figure 2a,b). Although we cannot rule out
the role of the particular sequence of the peptide substrate
sequence, this observation suggests that the two transferases
may indeed diﬀer in their binding mode of glycopeptide
substrates in the region spanning the lectin and catalytic
domain (Figure 3a,b).
Catalytic Domain Substrate Binding. At the catalytic
domain peptide-binding site of GalNAc-T4 bound to 6, most
of the interactions with the peptide are through direct and
water-mediated hydrogen bonds and to a lesser extent through
hydrophobic interactions. Direct hydrogen bonds are observed
with the Gly8/Ala9 and Pro13 peptide substrate backbone
carbonyls and the side chain NH’s of Arg372 and Trp286,
respectively, while a CH−π interaction takes place between
Pro15 and Trp286. The acceptor Thr12 side chain hydroxyl
group is hydrogen bonded to the UDP β-phosphate, showing
that this residue is well-located to accept the GalNAc moiety of
the UDP-GalNAc (Figure 3a,c). In addition, the Thr12 methyl
group is located in a hydrophobic environment formed by the
side chains of Phe284, Phe364, Trp286, and Ala310, as earlier
described for GalNAc-T2 (residues Phe280, Trp282, Phe361,
and Ala307) in complex with the mEA2 peptide (STCPA)
(PDB entry 4D0Z).18 We proposed that this environment
helps to correctly position the acceptor Thr hydroxyl group to
accept the anomeric carbon of UDP-GalNAc, thus enhancing
the turnover and further explaining why Thr residues are better
acceptors than Ser residues.18 Water-mediated hydrogen bonds
are observed through (1) Ala9/Gly10 and Gly16 backbone
with Ala368/Arg372 backbone and Thr258 side chain
hydroxyl, respectively; (2) Thr12 backbone with Arg 372
backbone; and (3) Thr12 side chain with Asn338 side chain
and Ala310 backbone (Figure 3a).
In contrast to the observations for 6 bound to GalNAc-T4,
most of the interactions of the MUC5AC-13 glycopeptide
(GTTPSPVPTTSTT*SAP) bound to GalNAc-T2 take place
through hydrophobic and water-mediated hydrogen bond
interactions, with few direct hydrogen bond interactions
(Figure 3b).13 Overall, our comparison of the GalNAc-T2
and -T4 peptide substrate bound structures demonstrates that
both employ a well-balanced number of direct and water-
mediated interactions that diﬀer in type and number. While the
complex of 6 with GalNAc-T4 mainly relies on direct
hydrogen bonds, the binding of MUC5AC-13 to GalNAc-T2
is dominated by multiple hydrophobic interactions. These
results may be due to both the diﬀerence between the residues
forming the peptide binding pocket and the diﬀerent peptide
substrate sequences. However, both enzymes share nearly
identical hydrophobic interactions that are used to recognize
the -PXP- motif found in both peptides, Pro13 in 6
(GAT*GAGAGAGT*TPGPG, italicized), and Pro6 in
MUC5AC-13 (GTTPSPVPTTSTT*SAP; Figure 3a,b). The
analysis of both crystal structures permits us to infer that the
relative promiscuity of both enzymes (outside the -PXP-
motif) for recognizing multiple and dissimilar protein/peptide
substrates relies on a combination of direct interactions of the
peptide substrate amino acid residues with the transferase and
with water-mediated hydrogen bond interactions. A similar
mechanism of protein substrate recognition has been described
for the promiscuous O-fucosyltransferase 2 (PoFUT2).25
Hence, this recognition event may be general for diverse
peptide substrates binding to enzymes.
GalNAc-T4 Catalytic Domain Glycopeptide-GalNAc Bind-
ing Site. A putative GalNAc binding site in the catalytic
domain of GalNAc-T4 proposed in our earlier random
glycopeptide studies10 has been conﬁrmed by the kinetics
and STD-NMR experiments described above. Such a binding
site is not present in GalNAc-T2.10 The structure of GalNAc-
T4 bound to diglycopeptide 6 (-T*--T*T-) clearly reveals the
GalNAc moiety on Thr11 (directly N-terminal of the acceptor
Thr12) tethered to the surface of the catalytic domain (Figure
3a). This binding event is mediated by hydrogen bond
interactions between GalNAc-O6 and the Lys336 backbone
carbonyl and between the carbonyl group of GalNAc and the
Gln285 side chain amide. In addition, water-mediated and
CH3/CH3 hydrophobic interactions are shown between the
GalNAc O6 and the Pro365 backbone carbonyl, and the
methyl group of GalNAc and the Thr283 methyl, respectively
(Figure 3a). As shown below, mutation of Thr283 and Gln285
signiﬁcantly alters GalNAc-T4’s neighboring glycopeptide
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activity. All together, these interactions show how the speciﬁc
GalNAc-Thr binding event at the catalytic domain directly
presents the adjacent C-terminal Thr acceptor into the correct
orientation for subsequent GalNAc transfer from the bound
UDP-GalNAc. Thus, in addition to the remote lectin bound
GalNAc residue, the presence of the neighboring substrate
GalNAc moiety together provides the speciﬁc and essential
contacts with the transferase that are required for optimal
activity.
GalNAc-T4 Nucleotide-Sugar Binding Site. Both GalNAc-
T2 and T4 share a very similar nucleotide-sugar binding sites
with ∼60% identical residues (Figure 3a,b). The UDP
pyrimidine moiety in GalNAc-T4 is sandwiched between
Tyr144 and Leu207 (His145 and Leu204 in GalNAc-T2),
while the Mn2+ ion is hexagonally coordinated by the UDP
pyrophosphate group, His362, the D227XH229 motif (His359
and D224XH226 in GalNAc-T2), and a water molecule (Figure
3a). UDP is mostly tethered by conserved hydrogen bonds
with Ala142, Asp175, Arg204, Cys228, Trp334, and Tyr370
that are also present in GalNAc-T2 (Thr143, Asp176, Arg201,
Ser225, Trp331, and Tyr367 in GalNAc-T2). Both enzymes
also share interactions between Tyr370 (Tyr367 in GalNAc-
T2) with the pyrophosphate moiety. The complex of GalNAc-
T4 shows a hydrogen bond between the Tyr144 backbone and
the uridine ribose, which is not found in that of GalNAc-T2.
However, most of the diﬀerences at this binding site between
both enzymes arise from the nonconserved amino acids in
their ﬂexible loops and the diﬀerences in peptide substrates.
For example, for GalNAc-T4, Arg372 and Pro365/Lys366
recognize the β−pyrophosphate/glycopeptide 6 and GalNAc
on Thr11, respectively, while, for GalNAc-T2, His365 and
Arg362 interact with theMUC5AC-13 substrate (Figure 3a,b).
Overall, our results conﬁrm that the recognition of UDP-
GalNAc is highly conserved between GalNAc-Ts, whereas the
nonconserved ﬂexible loop and the peptide-binding groove are
responsible for their diﬀerent peptide substrate speciﬁcity.
Correlation between Crystal Structure and STD-NMR. The
STD-derived epitope mapping reported in Figure 1c and
Figures S2−S6 is consistent with the X-ray crystal structure of
6 bound to GalNAc-T4. For the bound -T*TPGP- fragment at
the catalytic domain, the observed STDs for methyl group
protons of GalNAc and both Thr residues, together with the
CH2 protons of both Pro residues of compounds 4, 5, and 6,
are readily explained by the X-ray structure since all these
protons are in close contact to the transferase surface (Figure
S9). The sugar moiety appears relatively far from the catalytic
domain. However, the GalNAc moiety bound to the lectin
domain ﬁts into a cleft that displays multiple contacts,
including the NHAc methyl group protons (Figure S9).
These interactions account for the STD enhancements
observed for the GalNAc H2, H3, and H4 and NHAc methyl
protons in 3. All together, these results are fully consistent with
a model in which the bound GalNAc at the catalytic domain
shows poor contacts with the enzyme and therefore weak
STDs, while that bound at the lectin domain displays
important interactions with large STD enhancements.
GalNAc Binding Site Mutants of GalNAc-T4. To further
assess the roles of the individual lectin and catalytic domains
on the binding of GalNAc glycopeptide substrates, GalNAc
binding mutants were expressed for kinetic analysis against the
(glyco)peptide substrate library in Table 1. These were
designed to (1) eliminate the remote GalNAc binding site at
the lectin domain (lectin mutant); (2) attempt to eliminate the
neighboring GalNAc binding on the catalytic domain (catalytic
mutant); (3) understand the role of the lectin ﬂexible loop
(LFL mutant); (4) understand the combined role of the
catalytic domain and LFL on GalNAc binding (catalytic/LFL
mutant); and ﬁnally (5) understand the eﬀect of eliminating
both the lectin and catalytic domain GalNAc binding sites
(lectin/catalytic mutant). The results of these kinetic studies in
comparison to those carried out for wt GalNAc-T4 are given in
Figure 4 and Table 2. To summarize, the results clearly show
the expected eﬀects of the diﬀerent mutations. The remote
lectin domain glycopeptide activity is eliminated in the lectin
mutants (left panels Figure 4), while the neighboring
glycopeptide activity is reduced but not completely eliminated
in the catalytic domain and LFL mutants (right panels Figure
4). These ﬁndings show that it is possible to produce a
transferase that lacks one or the other prior GalNAc binding
activities or one that is nearly void of any prior glycosylation
activity. We discuss the obtained ﬁndings for each mutant in
more detail below.
Lectin Domain GalNAc Binding Mutant. To eliminate
the long-range (i.e., -T*--T*T- and -T*--TT-) glycopeptide
binding at the lectin domain, the critical Asp in the classical
CysLeuAsp (CLD) GalNAc binding motif was mutated to His
(D459H lectin mutant). Such Asp to His mutations in other
GalNAc-Ts, including T4, have been shown to eliminate their
lectin binding properties.11,26−29 Accordingly, the GalNAc-T4
D459H mutant shows a dramatic loss in its long-range prior
glycosylation activity against glycopeptides 3 and 6 (-T*--TT-
and -T*--T*T-) (Figure 4b, left panel), which can only be
observed in the expanded scale plot at the right (Figure 4b).
Thus, for 3, the Km increased ∼20-fold, and its Vmax decreased
over 1000-fold, approaching the activity of the naked peptide
1.14 For 6, Km also increased ∼20-fold, but its apparent Vmax
decreased only ∼5-fold, providing half of the activity of
glycopeptide 4 (Figure 4b). In addition, the nonproductive
UDP-GalNAc hydrolysis signiﬁcantly increased to ∼70% and
∼20%, for 3 and 6, respectively, in the lectin mutant, while for
the wt transferase hydrolysis is only ∼5% for both substrates
(Table 2 and Figure S8). These results clearly demonstrate the
role of the lectin domain in directing the long-range prior
glycosylation activity of GalNAc-T4 and that this is the
dominant activity of GalNAc-T4. Nevertheless, the mutant
displays a residual activity for glycopeptide 3 (-T*--TT-)
compared to peptide 1 (-TT-) and a slight substrate inhibition
for 6 that suggests that a weak lectin domain binding activity
remains in the mutant, probably due to weak binding at its β-
or γ-lectin subdomains.10
Although the GalNAc binding site of the catalytic domain
was unchanged, the glycosylation of 4, containing the
neighboring glycosylation motif -T*T-, was signiﬁcantly
higher, giving a ∼2-fold higher Vmax and catalytic eﬃciency
compared to the wt transferase. Moreover, the UDP-GalNAc
hydrolysis decreased by ∼1/2 (Figure 4b right, Figure S8, and
Table 2). We attribute this ∼2-fold increase in activity to the
loss of the nonproductive binding of -T*TPGP- at the lectin
domain in this mutant compared to the wt GalNAc-T4.
Interestingly, both diglycopeptides 5 and 6 (-T*T--T*- and
-T*--T*T-), which contain both the long-range and the
neighboring prior GalNAc residues, show about half of the
activity of glycopeptide 4 (-T*T-) (Figure 4b, right panel,
Table 2). This lower activity can be rationalized by recognizing
that diglycopeptides 5 and 6 contain two substrate GalNAc
residues that compete for binding at the catalytic domain
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GalNAc binding site. This competition process leads to a net
reduction in overall transfer, since only the bound -T*T-
sequence can be glycosylated. Thus, the observed rates of
glycosylation of the diglycopeptides should approach half of
that of glycopeptide 4 (Figure 4b and Table 2). Hence, the
kinetic parameters derived for monoglycopeptide 4 with this
“simpliﬁed” mutant likely represent the intrinsic rates of
GalNAc-T4 for glycosylating the -T*TPGP- sequence.
Catalytic Domain GalNAc Binding Mutant. Based on
the structure of the bound diglycopeptide 6 (-T*---T*T-), the
side chains of Thr283 and Gln285 of the catalytic domain are
the only potentially mutable residues involved in direct
interactions with the neighboring peptide GalNAc residue
(i.e., -T*T-) of the glycopeptide substrate. This catalytic
mutant (T283S/Q285A) was therefore expressed to disrupt
these interactions. As expected, the catalytic activities (Vmax)
against glycopeptide substrates 4 and 5 (-T*T-, -T*T--T*-),
were reduced to ∼1/3 of the wt GalNAc-T4 activity (Figure 4c
right, Table 2). This incomplete inactivation suggests that the
neighboring GalNAc binding site is only partially abolished in
this mutant, presumably due to the remaining GalNAc-peptide
backbone binding interactions shown in the crystal structure
(i.e., Lys336 and Pro365, Figure 3), which are not eliminated
by this mutation. Furthermore, the Km values for glycopeptides
4 and 5 were ∼2-fold higher than those of the wt and lectin
mutant GalNAc-T4. Finally, the small increase in non-
productive hydrolysis of UDP-GalNAc observed with these
glycopeptides correlates with the lower activity of glycopep-
tides 4 and 5 compared to the wt enzyme (Table 2 and Figure
S8). All together, these observations strongly suggest that the
-PGP- motif remains a signiﬁcant contributor to the binding of
substrate in the catalytic mutant.
To further conﬁrm that the catalytic mutant has reduced or
eliminated the −1 neighboring glycopeptide activity (i.e., for
the -T*T- motif), a random glycopeptide GPIID (GA-
GAXXXXXT*XXXXXAGAG, where X= GARPNEYV and T)
was glycosylated by the catalytic mutant and Edman amino
sequenced to determine the sites of 3H-GalNAc incorpo-
ration.10 As shown in Figure S10, the catalytic mutant clearly
showed a reduction of incorporation of 3H-GalNAc at the Thr
acceptor contiguous to the T* at the −1 site, compared to the
wt GalNAc-T4, further conﬁrming, in a nonambiguous
manner, the partial loss of the neighboring glycosylation
activity in this mutant.
As expected, glycosylation of 3 and 6 (-T*--TT- and -T*--
T*T-) by the catalytic mutant is dominated by their remote
prior glycosylation activity, due to GalNAc binding to the
lectin domain. Thus, the obtained kinetic plots are similar to
those for the wt GalNAc-T4 (Figure 4a,c), including the
presence of substrate inhibition for diglycopeptide 6. However,
6 displays a ∼4-fold higher Km and a ∼6-fold higher Kd by SPR
(Figure S11) and a ∼2-fold higher initial Vmax compared to the
wt transferase, resulting in about 1/2 the catalytic eﬃciency,
Vmax/Km (see Table 2). These higher Km and Kd values in the
catalytic mutant are consistent with a signiﬁcant loss of
GalNAc binding at the catalytic domain and the subsequent
loss of divalent binding to the enzyme, as compared to the
native GalNAc-T4. Although merely speculative, the observed
elevation in apparent Vmax for 6 could be explained by the loss
of nonproductive binding at the catalytic domain for the
remote -T*- substrate GalNAc residue, along with the weaker
binding of the lectin domain to the -T*TPGP- sequence
(Figure 4c and Table 2). Nevertheless, 6 still displays substrate
inhibition at high concentrations, presumably due to the onset
of nonproductive binding of the -T*TPGP- sequence at the
lectin domain competing with the productive binding of the
remote -T*-. In the catalytic mutant, monoglycopeptide 3
Figure 4. Enzyme kinetics of wt and mutant GalNAc-T4 against the
(glyco)peptide substrates in Table 1. Note that the left and right
panels are plotted with diﬀerent initial activity scales. Kinetic
constants obtained from the plots are given in Table 2. (a) Wild-
type GalNAc-T4 showing both long-range (left panel) and short-
range (right panel) glycopeptide activities. (b) Lectin mutant
(D549H) showing the loss of its long-range glycopeptide activity.
(c) Catalytic mutant (T283S, Q285A) showing the partial loss of
GalANc-T4’s short-range prior glycopeptide activity. (d) Lectin
ﬂexible link (LFL) mutant (P463DNNP467 to GGG) showing a partial
loss of the short-range glycopeptide activity while possessing an intact
catalytic domain. (e) Catalytic/LFL combined mutant (T283S,
Q285A, D464A) showing a more complete loss of the short-range
glycopeptide activity. (f) Lectin/catalytic combined mutant (T283S,
Q285A, D459H) showing the near complete loss of both the long-
range and short-range glycopeptide activities.
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(-T*--TT-) does not show any signiﬁcant increase in rate
compared to the wt transferase, likely due to the fact that the
catalytic domain GalNAc binding site has not been fully
inactivated in this mutation. As shown below, when the
catalytic domain GalNAc binding is more fully reduced, the
Vmax for 3 indeed increases. Finally, it should be mentioned
that the extent of nonproductive UDP-GalNAc hydrolysis for
glycopeptides 3 and 6 for the catalytic mutant are very low, as
observed for the wt GalNAc-T4, again consistent with their
high activities and lectin domain binding (Table 2 and Figure
S8).
Lectin Domain Flexible Loop Mutant. As mentioned
above, the structure of GalNAc-T4 bound to glycopeptide 6
displays a ﬂexible loop (LFL) protruding from the lectin
domain toward the catalytic domain bound GalNAc in the
-T*TPGP- sequence. The superposition of GalNAc-T4
structures in the apo form with those in complex with 3 and
6 revealed conformational changes in the LFL (see below and
Figure S12). Thus, a truncated mutant was generated, where
the 463PDNNP467 sequence located at the tip of the loop was
replaced by -GGG-. Surprisingly, this mutant gave nearly
identical reductions in catalytic eﬃciency against glycopeptides
4 and 5 as those obtained for the catalytic mutant (i.e., ∼50%
reductions compared to wt GalNAc-T4, Figure 4d and Table
2). These decreases were driven by Vmax and not by changes in
the Km values (Table 2). These results conﬁrm that this loop
plays a signiﬁcant role in the binding of the -T*TPGP-
sequence at the catalytic domain. It is also worth noting that
the neighboring glycosylation activity of the LFL mutant
against the random glycopeptide acceptor GPIID shows the
identical −1 glycosylation preference as the wt GalNAc-T4
(see Figure S10). Therefore, the loss of the lectin ﬂexible loop
does not alter its intrinsic glycopeptide speciﬁcity, which is
consistent with the LFL mutant having an intact catalytic
domain.
Further evidence that the LFL stabilizes both glycopeptide
and peptide substrate binding was deduced by the observation
that the nonproductive hydrolysis of UDP-GalNAc for
glycopeptides 4 and 5 increased to ∼50%. For peptides 1
and 2 (-TT- and -TT--T*), hydrolysis nearly doubled to
∼90%, compared to the wt transferase (Table 2 and Figure
S8). These signiﬁcant decreases in activity and increases in
UDP-GalNAc hydrolysis with an intact catalytic domain
strongly suggest that the LFL must play a signiﬁcant role in
transient substrate binding or recognition of both glycosylated
(-T*TPGP-) and nonglycosylated (-TTPGP-) substrates. This
is the ﬁrst example demonstrating that the lectin domain of a
GalNAc-T can directly modulate transferase catalytic activity
through its interactions with the substrate bound to the
catalytic domain.
As expected, the kinetic plots of the LFL mutant against
glycopeptides 3 and 6 (-T*--TT-, -T*--T*T-) were very
similar to those observed for the catalytic mutant and the wt
GalNAc-T4 enzymes, as they all contain an intact lectin
domain GalNAc binding site. For 3, the Km and Vmax values are
nearly the same with all three enzymes, except for a ∼2-fold
higher Km in the catalytic mutant (Table 2). For 6, a nearly 2-
fold higher apparent Vmax is observed in the LFL mutant as
compared to the wt GalNAc-T4. This number is similar to that
observed for the catalytic mutant. Interestingly, the Km value
for glycopeptide 6 in the LFL mutant appears slightly lower,
although within experimental error of the wt transferase, while
for the catalytic mutant the Km value is ∼3-fold higher (Table
2). Thus, the apparent catalytic eﬃciency, Vmax/Km, of
glycopeptide 6 is increased compared to the wt and catalytic
mutant GalNAc-T4. Since the LFL loop deletion/mutation is
located only 4 residues C-terminal away of the critical Asp459
of the lectin domain GalNAc binding CLD motif, it is
therefore possible that the LFL mutant’s GalNAc binding
properties are altered such that the binding of 6 is enhanced.
To further examine the eﬀects of the LFL mutation on the
structure of the LFL, molecular dynamics (MD) simulations
were performed. The wild-type GalNAc-T4 and its LFL
mutant, in complex with UDP-Mn+2 and peptide 6, were
employed as starting geometries for 0.5 μs MD simulations on
each (see MD simulations protocol for details). Both
complexes were stable through the complete MD trajectory.
Markedly, in the LFL mutant the modiﬁed loop (-GGG-)
provided an open-like structure and was rather ﬂexible. In
contrast, the wild-type enzyme showed a well-deﬁned loop
(-PDNNP-), with a closed-like structure (Figure S13). This
closed structure was stabilized by the formation of transient
hydrogen bonds between O3 of the Thr11 GalNAc residue
bound to the catalytic domain and the Asp464 side chain of
the lectin loop (Figure S14). These observations provide
further support to the hypothesis that the lectin ﬂexible loop,
and particularly Asp464, stabilizes the binding of neighboring
prior glycosylated peptide substrates containing the -T*TPGP-
motif. The MD simulations were further complemented with a
combination of steered molecular dynamics and umbrella
sampling simulations (see computational binding simulations)
that consisted of pulling out the glycopeptide 6 from the
catalytic domain of wt GalNAc-T4 (Figure S15). During this
process, the hydrogen bond between Asp464 and the Thr11-
GalNAc residue of 6 was lost and replaced with a transient
hydrogen bonding with the acceptor hydroxyl of Thr12
(Figure S15). These alternative simulations oﬀer further
support for a key role for the LFL and particularly Asp464
in substrate binding.
Combined Catalytic Domain and LFL Mutant. To
access the combined roles of the catalytic domain GalNAc
binding residues, T283 and Q285, and the LFL key D464, the
T283S, Q285A, D464A triple mutant was expressed and
puriﬁed (named as the catalytic/LFL mutant). It was expected
that this mutant would show further reduced activity against
the -T*TPGP- motif while retaining its long-range N-terminal
-T*- preferences. Indeed, the apparent activity and Vmax values
of 4 and 5 were reduced to ∼1/4 of the values for the catalytic
and LFL mutants (Figure 4e, right panel, Table 2).
Interestingly, their Km values were also reduced compared to
the wt and catalytic and LFL mutants; however, this may be an
artifact of the low activity of these substrates resulting in an
inadequate dynamic range for accurate data ﬁtting. As
expected, 3 and 6 displayed similar kinetic plots as the
individual mutants with intact lectin domain GalNAc binding
sites. However, both glycopeptides gave elevated apparent Vmax
values compared to the wt transferase. These ﬁndings are
consistent with the previous observation of higher rates of
glycosylation for the catalytic domain mutant. Note however
that the Km value for the diglycopeptide 6 in the catalytic/LFL
mutant was identical to that for the wt transferase and ∼4-fold
lower than that for the catalytic mutant. In contrast, the Km for
monoglycopeptide 3 was ∼2-fold higher than that for the wt,
but the same as that observed for the catalytic mutant (Table
2). Although a full explanation for all these observations
remains elusive, the catalytic/LFL mutant may nevertheless be
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considered a kinetically simpliﬁed version of GalNAc-T4, with
an intact N-terminal long-range prior glycosylation preference,
while nearly lacking its neighboring preference for GalNAc.
Finally, it is worth noting that the patterns of UDP-GalNAc
hydrolysis for both the LFL and catalytic/LFL mutants diﬀer
from the catalytic mutant, as shown in Figure S8. For both
LFL-containing mutants, the degree of hydrolysis in the
presence of 1 (-TT-), 2 (-TT--T*-), 4 (-T*T-), and 5 (-T*T--
T*-) is much higher than that with the catalytic mutant. The
fact that hydrolysis is doubled in the presence of both the -TT-
and -T*T- containing substrates that lack the N-terminal prior
-T* again suggests that the lectin ﬂexible loop plays an
important role in productive -TTPGP- and -T*TPGP-
substrate binding. Based on our previous experience with the
GalNAc-Ts, hydrolysis tends to correlate with poorer substrate
activity, which can be considered to represent incomplete or
poor binding of substrate. In fact, in the absence of any
(glyco)peptide substrate, hydrolysis is typically very low.10
Combined Lectin Domain and Catalytic Domain
Mutant. Next, an attempt to remove both the long- and
short-range prior glycosylation preferences of GalNAc-T4 was
carried out, by combining the lectin and catalytic domain
mutants. Thus, a new triple mutant (T283S, Q285A, D459H)
was generated, which will be called the lectin/catalytic mutant.
As shown in Figure 4f and Table 2, the target was largely
achieved, although a residual activity for those glycopeptides
containing the -T*TPGP- motif still remained. As discussed
above, this residual activity may be due to the remaining
GalNAc binding residues in the catalytic domain and/or to the
presence of Asp464 at the LFL lectin domain. Moreover, UDP-
GalNAc hydrolysis for all the substrates, except for
glycopeptides 4 and 5, were signiﬁcantly increased compared
to wt GalNAc-T4 (Figure S8), although hydrolysis in the
presence of (glyco)peptides 1, 2, 4, and 5 with this lectin/
catalytic mutant were still lower that those observed for both
LFL mutants. Together, these results further support the role
of the LFL assisting in binding substrates at the catalytic
domain and the dominance of the lectin domain binding
remote N-terminal glycosylated substrates.
Peptide Substrate Preferences of GalNAc-T4 and Its
Catalytic Domain Mutant. We have previously developed a
series of random peptide substrates, as GAGAXXXXXTXXXX-
XAGAG, (where X = randomized amino acids), to characterize
GalNAc-T peptide substrate preferences (see random peptide
sequence motif determination in the Methods section).30,31 By
using high enzyme and substrate concentrations along with
long incubation times, these substrates were glycosylated by
GalNAc-T4 and its catalytic mutant. Their substrate
preferences were evaluated in terms of the obtained enhance-
ment values (EVs) (Figures S16 and S17). As expected, both
wt and catalytic mutant transferases revealed preferences for
the TPXP motif, due to the presence of three highly conserved
Phe and Trp residues in the catalytic domain of most GalNAc-
T family members.10,13 GalNAc-T4 also revealed high
preferences at the −1 position (relative to the site of
glycosylation) for Val, Ile, and Met. On this basis, GalNAc-
T4 shows peptide substrate preferences fairly close to that of
GalNAc-T3.30 Regarding the question whether mutations in
the catalytic domain GalNAc binding site would alter its
“naked” peptide substrate speciﬁcity, particularly at the −1
position,10 no signiﬁcant diﬀerences in the preferences were
observed between the wt and mutant transferases (Figures S16
and S17). The observed preferences for Thr-O-GalNAc, Val,
and Ile at the −1 position could be related to the presence of
their β-branched methyl groups. Indeed, intense STDs are
observed for the Thr methyl protons in 4, 5, and 6 in the
presence of GalNAc-T4. The presence of methyl-containing
residues at the −1 site are likely related to the reported
conformational features provided by these residues.32
Thus, additional MD simulations were performed on
GalNAc-T4 complexed with UDP-GalNAc and a naked
peptide (GAGAGAGXTPGPG, where T is the acceptor
Thr) in which the residue X8 (−1 with respect to the acceptor
Thr) was replaced by either Val or Ala (Figure S18 and Movies
S1 and S2). According to the MD calculations, the peptide
containing the Val8 is stabilized by hydrophobic interaction
between the methyl groups of Val8 and Ala368. In turn, this
hydrophobic patch promotes the proximity between the
hydroxyl group of Thr9 and the anomeric carbon of GalNAc.
Conversely, the interactions between the methyl groups of
Ala8 and Ala368 in the Ala8 substrate were negligible,
presumably due to the longer distance between their
hydrophobic side chains, prompting Thr9 to move away
from the active site. These results satisfactorily explain why
GalNAc-T4 prefers β-branched amino acids at position −1 for
optimal glycosylation.
■ CONCLUSIONS
The GalNAc-Ts comprise a large family of evolutionary
conserved glycosyltransferase isoforms that diﬀerentially
exhibit substrate speciﬁcities for peptides and partially
glycosylated GalNAc-glycopeptides. All isoforms use their
unique C-terminal lectin domains to bind GalNAc-glycopep-
tides, and here for the ﬁrst time we demonstrate that a subset
of the GalNAc-T isoforms exempliﬁed by GalNAc-T4 also
contain a GalNAc binding site in the catalytic domain. We
provide the ﬁrst conclusive evidence for the direct interaction
of the catalytic domain with a GalNAc residue immediately
adjacent to the acceptor site explaining the observed GalNAc-
glycopeptide substrate speciﬁcity of GalNAc-T4 and related
isoforms. Unambiguous evidence for the two distinct GalNAc
binding capabilities was obtained by the structure of GalNAc-
T4 bound to a diglycopeptide (i.e., glycopeptide 6, -T*--T*T-
). This structure revealed how the catalytic domain of GalNAc-
T4 recognizes a glycopeptide substrate, and represents the ﬁrst
structure of a GalNAc-T with a glycopeptide GalNAc residue
bound to its catalytic domain.
Interestingly, the key residues at the catalytic domain
responsible for the binding of the neighboring GalNAc residue
have been identiﬁed, showing that the binding process is
dominated by rather weak interactions, as further supported by
kinetic studies. When both long- and short-range prior
glycosylation sites are combined in one substrate, i.e.,
diglycopeptide 6, apparent substrate inhibition is observed.
Comparing the kinetics of the mutant and wt transferases
suggests that the observed inhibition may be due to the weak
nonproductive binding of the substrate -T*TGPG- sequence
at the lectin domain. This competition with the binding of the
remote GalNAc at high substrate concentrations then leads to
a decrease in activity. This observation furthermore suggests
the lectin domain of GalNAc-T4 may also possess unique
peptide sequence preferences as found for GalNAc-T2.28
A unique aspect of this enzyme is the presence of a ﬂexible
loop (LFL) protruding from the lectin domain, which assists
both GalNAc binding and release. We believe that with this
ﬁnding we have identiﬁed a new structural feature, out of the
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few already described for GalNAc-Ts, that serves to modulate
GalNAc-T4 activity and speciﬁcity. Thus, alterations outside
the catalytic domain and the lectin domain GalNAc binding
sites, that would not be predicted to be deleterious, can have
profound eﬀects on the catalytic activity of GalNAc-T4.
In addition, the generation of several GalNAc-T4 mutants
has allowed us to individually characterize the kinetics and
binding features of the diﬀerent parts of the enzyme. Finally,
the “naked” peptide substrate motif for GalNAc-T4 and its
catalytic domain mutants reveals that GalNAc-T4 displays the
expected TPXP preference and prefers the β-branched residues
Val, Ile, and Met residues preceding its acceptor site.
In summary we have identiﬁed the molecular basis for
GalNAc-T4’s long- and short-range prior GalNAc glycosyla-
tion preferences, demonstrating that the long-range speciﬁcity
greatly dominates the activity/function of this isoform. The
combination of long- and short-range GalNAc-glycopeptide
substrate speciﬁcity makes GalNAc-T4 ideal for performing the
proposed role as a follow-up isoenzyme that ﬁlls in unoccupied
acceptor sites in densely O-glycosylated regions such as in the
tandem repeats of mucins.11,21 This is consistent with GalNAc-
T4’s high expression levels in mucin secreting tissues such as
the colon, lung, and sublingual gland.1,33 Our newly acquired
ability to selectively eliminate the long- and/or short-range
glycopeptide activities of GalNAc-T4, based on the crystal
structure of GalNAc-T4-UDP-glycopeptide 6 complex, will be
an invaluable tool for understanding how GalNAc-T4 performs
this important ﬁlling-in role.
■ METHODS
Cloning, Site-Directed Mutagenesis, Expression, and
Puriﬁcation. The expression plasmid pPICZαAgalnact4 (36−
578) was used as the template for introducing the following
single and multiple amino-acid changes by site-directed
mutagenesis as described:14 T283S-Q285A (catalytic mutant),
D459H (lectin mutant), T283S-Q285A-D459H (lectin/
catalytic mutant), and T283S-Q285A-D464A (catalytic/LFL
mutant). For generating the lectin ﬂexible loop deletion
mutant (LFL mutant), the residues P463DNNP467 were
removed and replaced by three Gly residues. Site-directed
mutagenesis was performed by GenScript. Wild-type and
mutant transferases were puriﬁed using the protocol developed
for the wild-type enzyme.14
Synthesis of Glycopeptides. Glycopeptides were synthe-
sized as described previously and conﬁrmed by Edman amino
acid sequencing on a Shimadzu PPSQ-53A peptide
sequencer.14 See Table S5 for the HPLC and MS character-
ization of each glycopeptide.
Transferase Assays and Kinetics. GalNAc-T glycosyla-
tion reactions against (glyco)peptides 1−6 were performed as
described.14 Brieﬂy, reactions consisted of 75 mM sodium
cacodylate, pH 6.5, 1 mM 2-mercaptoethanol, 10 mM MnCl2,
0.25 mM [3H]-radiolabeled UDP-GalNAc (∼6 × 108 DPM/
μmole, American Radiolabeled Chemicals Inc.), and 0.004−1.4
mM of glycopeptide substrate and variable concentration of
transferase (0.02−0.2 μM) in a ﬁnal reaction volume of 20 μL.
After incubating at 37 °C reactions were quenched by the
addition of 20 μL of 250 mM EDTA. UDP and nonhydrolyzed
UDP-GalNAc were removed by passage over a small Dowex 1
× 8 anion exchange resin. Total UDP-[3H]-GalNAc utilization
(transfer to peptide substrate plus transfer to water, i.e., UDP-
[3H]-GalNAc hydrolysis) was determined by scintillation
counting (Beckman LS5801 scintillation counter) aliquots
before and after passage over Dowex. The actual [3H]-GalNAc
transfer to peptide and the extent of hydrolysis were
determined by gel ﬁltration analysis on Sephadex G10, as
described.19 Example gel ﬁltration chromatograms are given in
Figure S8. In all cases the reported transferase activity has been
corrected (reduced) for the presence of the nonproductive
UDP-[3H]-GalNAc hydrolysis which varied with the glycopep-
tide substrate and with the transferase mutant. For detailed
kinetics studies incubation times (typically 10−180 min) were
chosen such that no more than 30% of the UDP-GalNAc
donor was depleted while typically giving less than 10%
(glyco)peptide glycosylation. Initial velocities/activities were
determined using 1 or 3 reaction time points for each substrate
concentration and were repeated 2−5 times. Typically 24−30
individual speciﬁc activity values were obtained over the entire
substrate concentration range. These individual data points
were used to calculate the kinetic constants of Km, Vmax, and Ki
using the nonlinear Michaelis−Menten and the Michaelis−
Menten with substrate inhibition ﬁtting programs found in
GraphPad Prism 7.03.
Random Peptide Sequence Motif Determination.
Peptide sequence motifs for GalNAc-T4 and its mutants
were obtained as described for other GalNAc-Ts.31,34,35 Brieﬂy
overnight transferase reactions (0.3 μM enzyme) were
performed with each of the 3 random peptides PVI, PVII,
and PVIII (GAGAXXXXXTXXXXXAGAGK, where X =
G,A,R,P,E,H,Q,Y,V,L (PVI), G,A,P,R,D,F,I,M,K,N (PVII),
and G,A,P,R,E,Y,V,K,N,S (PVIII))30 at ∼6.6 mM in the
presence of 200 mM sodium cacodylate, pH 6.9, 1 mM 2-
mercaptoethanol, 10 mM MnCl2, 0.1% TritonX100, and 2 mM
[3H]-radiolabeled UDP-GalNAc (∼6 × 108 DPM/μmole,
American Radiolabeled Chemicals Inc.) in a ﬁnal volume of
200 μL. Reactions were quenched with 100 μL of 250 mM
EDTA, passed over Dowex 1 × 8 anion exchange resin and
peptide and glycopeptide products isolated by Sephadex G10
gel ﬁltration. Glycopeptide product was isolated by lectin
chromatography on a mixed bed lectin column containing
immobilized lectins (SJA (Sophora japonica), SBA (Glycine
max), HPA (Helix pomatia), and VVA (Vicia villosa)) as
described.31 After ﬁnal puriﬁcation on Sephadex G10
chromatography the glycopeptide product was Edman amino
acid sequenced on a Shimadzu PPSQ-53A peptide sequencer
to determine the compositions of the X positions of the
random peptides. Enhancement values (EVs) were obtained
from the ratio of the mole fractions of each amino acid residue
in the product glycopeptide to that in the starting random
peptide.31 Thus, EVs greater than one indicate an enrichment
in the glycopeptide while EVs lower than 1 indicate a depletion
in the glycopeptide. On this basis the EVs reﬂect the
transferase’s preference for a particular amino acid residue at
each X position.30,31 EVs were obtained from triplicate
determinations on each random peptide; thus for each
amino acid residue there were between 3 and 9 individual
EV determinations at each X position depending on their
presence in the three diﬀerent random peptides. The obtained
averaged EVs are plotted and compared in Figures S16 and
S17 for wt and catalytic mutant GalNAc-T4.
Determination of Site of Glycosylation. Substrate
glycosylation sites were determined by Edman amino acid
sequencing on a Shimadzu PPS-Q53A protein sequencer.
Brieﬂy, G10 isolated [3H]-GalNAc glycosylated substrates
were spotted on a Polybrene precycled glass ﬁber disk (GFD)
and sequenced using a modiﬁed GFD program. The
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glycosylated PTH-Thr derivatives (eluting between 2.85 and
3.5 min using the standard PPSQ HPLC buﬀers and ﬂow rate)
were collected directly into scintillation vials on a Shimadzu
FRC-10A fraction collector and scintillation counted for [3H]-
GalNAc content (Beckman LS5801 scintillation counter).
Note that [3H]-GalNAc lag is commonly observed after a peak
of [3H]-GalNAc incorporation in these determinations. This is
due to the poor extraction of the glycosylated-PTH residues
from the glass ﬁber disks compared with the nonglycosylated
amino acid PTH derivatives.10,19
Surface Plasmon Resonance Experiments. The SPR
experiments for peptides 4 and 6 were performed as described
for glycopeptide 3.14 As found for peptide 3, binding saturation
was not achieved for glycopeptide 4; thus its Kd could not be
determined. However, saturation was reached for glycopeptide
6 allowing an accurate Kd determination.
NMR Experiments. All NMR experiments were recorded
on a Bruker Avance 600 MHz spectrometer equipped with a
triple channel cryoprobe head. The 1H NMR resonances of the
glycopeptides 4, 5, and 6 were completely assigned through
standard 2D-TOCSY (30 and 80 ms mixing time) and 2D-
NOESY experiments (400 ms mixing time) obtained at 278 K.
Glycopeptides were 1−3 mM in 25 mM perdeuterated tris-d11
(uncorrected pH meter reading 7.4) in H2O/D2O (90:10)
with 7.5 mM NaCl and 1 mM DTT. The resonance of 2,2,3,3-
tetradeutero-3-trimethylsilylpropionic acid (TSP) was used as
a chemical shift reference (δ TSP = 0 ppm) in the 1H NMR
experiments. Peak lists for the 2D-TOCSY and 2D-NOESY
spectra were generated by interactive peak picking using CARA
software. STD-NMR experiments were performed at 298 K in
deuterated water in the presence of 25 mM perdeuterated tris-
d11 (uncorrected pH meter reading 7.4), 7.5 mM NaCl, and 1
mM DTT, using ∼877 μM glycopeptide, 13.5 μM GalNAc-T4,
75 μM UDP, and 75 μM MnCl2. STD-NMR spectra were
acquired and the data analyzed as described.14
Crystallization. Crystals of GalNAc-T4 were grown as
described before.14 The crystals were soaked for 30 min with a
mix containing 20 mM glycopeptide 6 and 20 mM UDP in 25
mM Tris pH 7.5 and 2 mM MnCl2. The crystals were
subsequently cryoprotected with 25% ethylene glycol, 18%
PEG3350, and 0.1 M ammonium nitrate, and frozen in a
nitrogen gas stream cooled to 100 K.
Structure Determination and Reﬁnement. Diﬀraction
data were collected on the synchrotron beamline I03 of the
Diamond Light Source (Harwell Science and Innovation
Campus, Oxfordshire, UK) at a wavelength of 0.97 Å and
temperature of 100 K. Data were processed and scaled using
the XDS package36 and CCP437,38 software. Relevant statistics
are given in Table S4. The crystal structure was solved by
molecular replacement with Phaser37,38 using the PDB entry
5NQA of human GalNAc-T4 as template. Initial phases were
improved by several cycles of manual model building in Coot39
and further reﬁned using REFMAC5.40 The ﬁnal model of
GalNAc-T4 soaked with glycopeptide 6 and UDP was
validated with PROCHECK where model statistics are given
in Table S4. The asymmetric unit of the triclinic crystal
contained 2 molecules of GalNAc-T4 while only one of the
monomers contained UDP, Mn+2, and glycopeptide 6. The
Ramachandran plot shows that 95.14%, 3.69%, and 1.17% of
the amino acids are in most favored, allowed, and disallowed
regions, respectively.
MD Simulations with Peptide and Glycopeptide
Substrates. The wild-type and the LFL mutant of GalNAc-
T4, both in complex with UDP-Mn+2 and the glycopeptide 6,
were subjected to 500 ns of MD simulation as described
previously.14 Similarly, the wild-type GalNAc-T4 in complex
with UDP-GalNAc and a naked peptide (GAGA-
GAGXTPGPG where X denotes either Val or Ala and T as
the acceptor Thr) was subjected to 200 ns of MD simulations.
In all cases mutants were generated using PyMol. The starting
coordinates of the UPD-GalNAc in GalNAc-T4 were taken
from the X-ray structure of GalNAc-T2 previously reported by
our group (PDB ID: 4D0T).
Glycopeptide Pull-Out Computational Details. The
initial structure for the simulations was taken from the
GalNAc-T4-UDP-glycopeptide 6 complex. The UDP substrate
was completed adding the GalNAc sugar from the PDB entry
4D0T by superimposition. The protonation states and
hydrogen atom positions of all amino acid residues were
determined by visual inspection according to protein environ-
ment. The system was solvated with a box of 15 Å around the
protein surface (31.595 water molecules), and the global
charge was neutralized by the addition of 1 sodium ion, leading
to a total of 103 442 atoms. Molecular dynamics (MD)
simulations using Amber11 software were performed. The
protein was modeled with the FF99SB force ﬁeld, and the
carbohydrate substrate and water molecules were described
with the GLYCAM06 and TIP3P force ﬁelds, respectively. The
MD simulation was carried out in several steps. First, the
system was minimized, holding the protein and substrate ﬁxed.
Then, the entire system was allowed to relax. To gradually
reach the desired temperature, weak spatial constraints were
initially added to the protein and substrate, while water
molecules and sodium ions were allowed to move freely at 100
K. The constraints were then removed, and the working
temperature of 300 K was reached after two more 100 K
heatings in the NVT ensemble. Afterward, the density was
converged up to water density at 300 K in the NPT ensemble,
and the simulation was extended to 50 ns in the NVT
ensemble. Steered molecular dynamics41 (SMD) and umbrella
sampling42 (US) simulations were performed to pull out the
neighboring glycan from the catalytic domain. The ﬁrst
method was used to generate the initial pathway from which
the last method explored the phase-space. One collective
variable (CV) was used for the pull-out, deﬁned as the distance
between the α-carbon of Asn224 (buried in the binding pocket
of the catalytic domain) and the α-carbon of Thr12 (the
acceptor threonine of diglycopeptide 6). A total of 20
trajectories with random velocities were taken from the
reference structure from the equilibration MD, allowing them
to relax for 1 ns. Subsequently, a movable harmonic potential
of 50 kcal/(mol A2) was used to drive the CV 40 Å apart
during 2 ns, with a pulling velocity of 20 Å/ns. The trajectory
with the lower energy was taken for the US simulations, and
the pathway was divided in 81 windows with a regular
separation of 0.5 Å between them. Force constants of 10 kcal/
(mol A2) were used for the harmonic potentials. Every window
was sampled during 10 ns, leading to a total of ∼0.8 μs of
simulation data. The ﬁrsts 2 ns of each window were
considered as an equilibration step. Analysis of the trajectories
was carried out using standard tools of Amber and VMD.43
Particularly, the hydrogen bond analysis was performed using
the cpptraj utility from Amber14, taking into account all the
interactions between the substrate (diglycopeptide) and the
receptor (GalNAc-T4 bound to UDP-GalNAc), with a
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distance cutoﬀ of 3.0 Å between heteroatoms and 135° for the
angle that deﬁnes the hydrogen bond.
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